1 min read

A Gel That Talks the Brain Into Making New Neurons

An IV-delivered nanogel crossed one of medicine's toughest barriers and triggered something researchers have struggled for years to reproduce.

A gel injected into the bloodstream crossed into the brains of mice and triggered the appearance of new neurons. The raw material was already there: astrocytes, the support cells that normally help keep neurons alive and functioning.

The research, published in Cell Biomaterials, targets PTBP1, a protein that helps astrocytes maintain their identity. Lowering PTBP1 has previously been reported to convert astrocytes into neurons, but other labs struggled to reproduce the effect. This team tried a different approach.

They packaged antibodies against PTBP1 inside a targeted nanogel called Nano-ERASER. Delivered by IV, the gel crossed the blood-brain barrier, entered astrocytes and broke down PTBP1 without genetically modifying the cells.

In cultured human astrocytes, treated cells developed neuronal markers and fired synchronized electrical signals. Human brain organoids showed similar changes.

Then came mice engineered to develop Alzheimer's-like disease. After two IV doses eight days apart, treated mice performed better on tests of memory and nest building. Their brains also contained more neurons and less inflammation.

There is an important catch. Researchers have not yet definitively proved that all of the apparent new neurons inside living animals actually began as astrocytes. Long-term safety is also unknown, and human trials remain a distant prospect.

Still, an injectable material crossed the blood-brain barrier and apparently unlocked a regenerative program inside the brain. That's a door worth keeping open.

Read the full story at Live Science, August 26, 2026


Hot Take: The graveyard of promising Alzheimer's mouse studies is crowded. But an IV gel getting across the blood-brain barrier and coaxing brain cells toward a neuronal identity deserves a big red circle around it.

Subscribe to our newsletter.

Be the first to know - subscribe today